BRCA1 and ovarian cancer: Analysis of clinical ovarian cancer samples showed that exon 11 mutation carriers had worse overall survival when compared with non-exon 11 mutation carriers, probably due to less sensitivity to platinum-based chemotherapy by the cells with residual BRCA1 function of the hypomorphic protein [43].